

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of PuraPharm Corporation Limited (the “**Company**”) hereby announces that on 9 May 2019 the Board resolved to grant share options (the “**Options**”) to certain Directors and employees of the Company (the “**Grantees**”), subject to the acceptance of the Options and the payment of HK\$1 by each of the Grantees, entitling them to subscribe for a total of 6,376,000 ordinary shares of the Company (each a “**Share**”) under the share option scheme adopted on 12 June 2015. Details of the Options granted are set out below:

Date of grant	: 9 May 2019 (the “ Date of Grant ”)
Total number of Shares issuable under Options granted	: 6,376,000 Options, each Option shall entitle the holder of the Option to subscribe for one Share
Exercise price of the Options	: HK\$2.4 per Share, which represents the highest of (i) the closing price of HK\$2.4 per Share as stated in the Stock Exchange’s daily quotation sheets on the Date of Grant; (ii) the average closing price of HK\$2.148 per Share as stated in the Stock Exchange’s daily quotation sheets for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of US\$0.1 per Share.
Closing price of the Options on the Date of Grant	: HK\$2.4 per Share

- Validity period of the Options : Ten years, from 10 May 2019 to 9 May 2029
- Vesting schedule of the Options : (i) 2,975,500 Options granted will be vested on 10 May 2020;
- (ii) 2,975,500 Options granted will be vested on 10 May 2021;
- (iii) 212,500 Options granted will be vested on 10 May 2022; and
- (iv) 212,500 Options granted will be vested on 10 May 2023.

Out of the above 6,376,000 Options granted, 5,526,000 Options were granted to the Directors of the Company, details of which are set out below:

Name of Director	Position held with the Company	Number of Options granted
Mr. Chan Yu Ling, Abraham	Chairman, Chief Executive Officer, Executive Director, and substantial shareholder	2,083,000
Mr. Chan Kin Man, Eddie	Executive Director	2,083,000
Dr. Tsoi Kam Biu, Alvin	Executive Director and Vice Chairman	680,000
Ms. Man Yee Wai, Viola	Executive Director and substantial shareholder	680,000

The grant of the Options to the above Directors and the substantial shareholders has been approved by the Independent Non-executive Directors in accordance with rule 17.04(1) of the Listing Rules.

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined under the Listing Rules).

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 9 May 2019

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Chow, Stanley; and the independent non-executive Directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.